Bristol-Myers Squibb BMY Divestiture Gains And Royalties

Divestiture Gains And Royalties at other companies

MVB Financial Corp.MVBF

$0—

Service Corporation InternationalSCI

$2.39M-15.8%

Nutanix, Inc.NTNX

$0—

Wyndham Hotels & Resorts, Inc.WH

$139M-5.4%

Service Corporation InternationalSCI

$138K+103%

Warrior Met CoalHCC

$143.29M+90.9%

FAQ

What is Bristol-Myers Squibb's divestiture gains and royalties?

Bristol-Myers Squibb (BMY) reported divestiture gains and royalties of $142M in Q2 2026.

How has Bristol-Myers Squibb's divestiture gains and royalties changed year-over-year?

Bristol-Myers Squibb's divestiture gains and royalties decreased by 51.5% year-over-year, from $293M to $142M.

What is the long-term trend for Bristol-Myers Squibb's divestiture gains and royalties?

Over 3 years (2021 to 2024), Bristol-Myers Squibb's divestiture gains and royalties has grown at a 17.8% compound annual growth rate (CAGR), from $684M to $1.12B.

What does divestiture gains and royalties mean?

This captures cash inflows or accounting adjustments related to the sale of business units, product lines, or ongoing royalty streams from licensed intellectual property. It reflects the monetization of non-core assets or the recurring revenue from past R&D successes.